Scleroderma Clinical Trials

48 recruitingLast updated: June 17, 2026

There are 48 actively recruiting scleroderma clinical trials across 34 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1. Top locations include Ann Arbor, Michigan, United States, New York, New York, United States, Toulouse, France. Updated daily from ClinicalTrials.gov.


Scleroderma Trials at a Glance

48 actively recruiting trials for scleroderma are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Not Applicable with 10 trials, with the heaviest enrollment activity in Ann Arbor, New York, and Toulouse. Lead sponsors running scleroderma studies include University Hospital, Strasbourg, France, Hacettepe University, and Firat University.

Browse scleroderma trials by phase

Treatments under study

About Scleroderma Clinical Trials

Looking for clinical trials for Scleroderma? There are currently 31 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Scleroderma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Scleroderma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 48 trials

Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis

Healthy VolunteersSclerodermaSystemic Sclerosis (SSc)+1 more
Prolium Bioscience, Inc74 enrolled2 locationsNCT07641634
Recruiting
Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Scleroderma, Diffuse
Novartis Pharmaceuticals96 enrolled87 locationsNCT06655896
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled52 locationsNCT06991114
Recruiting
Phase 1Phase 2

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777
Recruiting
Not Applicable

Skeletal Muscle Function in Interstitial Lung Disease

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisScleroderma+2 more
University of British Columbia40 enrolled1 locationNCT03800017
Recruiting

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

MORPHEAScleroderma, LocalizedFrontal Linear Scleroderma en Coup de Sabre+2 more
University of Texas Southwestern Medical Center500 enrolled1 locationNCT01808937
Recruiting
Phase 1

Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)

Rheumatoid ArthritisSclerodermaSystemic Lupus Erythematosus
Shenzhen MagicRNA Biotechnology Co., Ltd30 enrolled1 locationNCT06801119
Recruiting

Trichoscopy and Systemic Scleroderma

Scleroderma, Systemic
University Hospital, Lille200 enrolled1 locationNCT04804930
Recruiting
Early Phase 1

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

Systemic Scleroderma
City of Hope Medical Center15 enrolled1 locationNCT04380831
Recruiting

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

Inflammatory Bowel DiseasesSclerodermaVasculitis+2 more
University Hospital, Toulouse3,000 enrolled1 locationNCT05251415
Recruiting
Not Applicable

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

SclerodermaMyasthenia Gravis (MG)System Lupus Erythematosus(SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07470151
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Phase 2

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

SclerodermaSystemic Sclerosis (SSc)
Zura Bio Inc80 enrolled51 locationsNCT06843239
Recruiting
Phase 2

Platform Clinical Study for Conquering Scleroderma

SclerodermaInterstitial Lung Disease Due to Systemic Disease
Scleroderma Research Foundation, Inc.400 enrolled34 locationsNCT06195072
Recruiting

Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma

Scleroderma
Centre Hospitalier Universitaire Dijon60 enrolled1 locationNCT07256418
Recruiting
Not Applicable

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

Systemic SclerodermaDiffuse Cutaneous Scleroderma
Boston University65 enrolled1 locationNCT07090226
Recruiting
Phase 2Phase 3

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Scleroderma, SystemicSystemic Sclerosis Associated Interstitial Lung Disease
GlaxoSmithKline300 enrolled131 locationsNCT05878717
Recruiting

Western Sweden Systemic Sclerosis Project

Fibrosis LungScleroderma, SystemicInterstitial Lung Disease Due to Systemic Disease+1 more
Sahlgrenska University Hospital150 enrolled1 locationNCT07345052